Pancreatic Cancer Research

ResearcherYamagata UniversityNo recent work listed

Chifumi Kitanaka

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5037577584. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
6
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper

Papers 4

  1. Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1-JNK axis. Last author DOI 10.1074/jbc.ra120.015223↗
  2. Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13667↗
  3. Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine. Last author DOI 10.21873/anticanres.11227↗
  4. JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells. Last author DOI 10.18632/oncotarget.2693↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shuhei Suzuki · 4 shared papers, 2015–2020 · strength 0.33
  2. Tomomi Sanomachi · 3 shared papers, 2016–2020 · strength 0.28
  3. Masahiro Yamamoto · 2 shared papers, 2019–2020 · strength 0.22
  4. Takashi Yoshioka · 3 shared papers, 2015–2019 · strength 0.21
  5. Atsushi Satō · 2 shared papers, 2015–2020 · strength 0.17
  6. Hiroyuki Takeda · 2 shared papers, 2015–2016 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.